Innovate UK award BioMoti, Pharmidex and Queen Mary University of London Biomedical Catalyst grant

December 5, 2017

Exciting project involving BioMoti, Pharmidex and Queen Mary University.

BioMoti (London, UK), Pharmidex (London, UK) and Queen Mary University of London (London, UK) have been awarded a grant of £662,222 following the Biomedical Catalyst funding competition from Innovate UK (Swindon, UK).

The grant was awarded to support the preclinical studies of the development of novel therapeutic approaches for hard to treat tumors, including advanced ovarian, triple negative breast and pancreatic cancers. Cofunded by a further £226,769 investment from BioMoti and Pharmidex, the project focuses on Oncojan™ from BioMoti, described as a ‘sustained release precision therapeutics platform targeting CD95L mediated tumor immune evasion’. With expertise in preclinical drug development from Pharmidex and mechanisms of disease from Queen Mary University of London, the trio will investigate precision delivery of drugs to solid tumor sites and immune system activation due to CD95L targeting on tumors over the next 2 years. “It is exciting for us to be supported by Innovate UK to explore our platform’s interactions with the immune system following promising efficacy data in cancer models. BioMoti is making great progress on a final seed investment round to support commercialisation and we welcome enquiries from qualified investors,” commented Davidson Ateh (BioMoti). “We are very pleased to join BioMoti and Queen Mary University of London in the preclinical development of the Oncojan™ platform.

This Innovate UK funded project is an exciting approach to cancer therapy that could have a significant impact on patient lives,” stated Chris Ireson (Pharmidex). “We are passionate about what a difference we could make for patients, and it is great to have secured Innovate UK funding,” concluded Joanne Martin (Queen Mary University of London).

Please see the link for more information: www.biomoti.com/biomoti-pharmidex-and-queen-mary-university-of-london-secure-662222-biomedical-catalyst-award/

< Older Post

Newer Post >

Pharmidex at the "Creative Disruption Forum: Modern Drug Discovery in Cambridge."

June 17, 2026

On 18 June, our COO, Ash Alavijeh , will join an industry panel discussing: "What are the advantages and disadvantages of working with UK-based Discovery CROs?" The session will explore the value of UK CROs in supporting innovation, protecting IP, accessing scientific expertise and accelerating drug discovery programmes. 📅 18 June 2025 📍 Cambridge 🕒 Panel Session: 12:20–12:45 We look forward to connecting with colleagues, collaborators, and innovators from across the life sciences community.

Congratulate Dr Mansoor Chishty as Director of DMPK at Pharmidex

June 16, 2026

This well-deserved appointment marks an important milestone in a remarkable career spanning more than 22 years at Pharmidex . Over the years, Dr Chishty has made a significant contribution to the growth of our DMPK capabilities, applying his extensive expertise in Drug Metabolism and Pharmacokinetics to support successful drug discovery and development programmes for clients worldwide. His scientific leadership, dedication and commitment to excellence have been instrumental in strengthening our services and supporting the continued success of Pharmidex . As we continue to grow and support innovative biopharmaceutical companies, we look forward to the impact Dr Chishty will make in this new role. Please join us in congratulating Dr Mansoor Chishty on this achievement and wishing him every success as Director of DMPK.

Pharmidex Embraces the Spirit of World Football 2026!

June 12, 2026

At Pharmidex , we know that great teams are built through collaboration, resilience and shared experiences. Our recent football event brought colleagues together to promote wellbeing, encourage physical activity and strengthen the relationships that help us succeed both on the pitch and in the laboratory. The qualities that drive success in sport, teamwork, dedication and determination are the same values that underpin scientific excellence every day at Pharmidex . As the world looks ahead to the excitement of World Football 2026, we're proud to celebrate the positive impact sport has in bringing people together, inspiring healthy lifestyles, and creating stronger communities. 🔬 Advancing science 🤝 Building stronger teams 💪 Promoting wellbeing ⚽ Celebrating our passion for sport And while football fans may be singing "It's coming home"... at Pharmidex we're convinced that "It's coming lab!" 🧪⚽ From the pitch to the lab, we're proud to champion teamwork, innovation, and a shared passion for achieving great results.